NCT07444073Not yet recruiting
Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 440 (estimated)
- First submitted
- 12 Feb 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National University of Singapore
- Diseases
- Obesity
- NCT number
- NCT07444073
What you commit to
- Study type: Observational
- Planned participants: 440
- From 1 Jun 2026 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.
Other illness
- Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.
- Active cancer on chemotherapy or immunotherapy.
- Known hypersensitivity or contraindications to GLP-1 RAs.
- Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.
Other
- Pregnancy or lactation.
- Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.
Who the study is looking for
- Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.
- BMI of ≥ 30 kg/m2 (obesity); OR
- BMI of ≥ 27 kg/m2 to \< 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
Age in the registry: 40 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National University of Singapore Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
| NOVI Health (T3 Health PTE LTD) Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.